Psychedelic Investors

Early-stage venture firm founded in 2020 investing across mental health and wellbeing, including psychedelic-assisted therapies, novel drug therapeutics, digital health and neurotech. Fund I made roughly 20 investments; the firm has since launched a second fund.

Source

A fully-invested $30M+ venture fund focused on CNS and brain-health therapeutics, backing pre-clinical and Phase 1 companies developing psychedelic-derived drugs. Its portfolio has seen exits to AbbVie, Otsuka and the public markets.

Source

Venture firm founded in 2021 by Dustin Robinson and Robert Velarde, backing companies across the psychedelic value chain — APIs, drug development, clinics and technology. Closed an inaugural fund of over $20M and founded Nucleus Holding, whose subsidiaries include Psychedelic Invest.

Source

NYC-based venture fund founded in 2019 investing at the intersection of neuroscience, technology and psychedelic medicine, primarily at Seed and Series A. Its largest holding, Gilgamesh Pharmaceuticals, struck a deal with AbbVie in 2025.

Source

U.S.-based psychedelic healthcare venture fund formed in 2020 by Daniel Goldberg, Tim Schlidt and Tony Eisenberg. Closed a $50M fund and is invested in 20+ portfolio companies spanning biopharma, drug development, digital therapeutics and health services.

Source

Early-stage venture firm investing in psychedelic medicine companies targeting mental health, addiction and pain, with a portfolio spanning drug developers, retreats and platforms.

Source

Early-stage venture firm founded in 2020 by Dina Burkitbayeva, Greg Kubin and Matias Serebrinsky, investing in frontier brain and mental-health technology including psychedelic medicine, neurotech and precision psychiatry. Manages a $25M fund plus an active angel syndicate.

Source

Life-sciences venture firm focused on novel modalities for mental health and wellbeing, including MDMA, psilocybin and ketamine therapies. Notably structured a $70M regenerative-financing deal with MAPS to fund MDMA-assisted therapy.

Source

Venture firm founded in 2021 (led by Brom Rector) investing in pre-seed and seed psychedelic medicine and health technology, with checks of roughly $100K–$2M. The firm has since rebranded (XEIA Venture Partners / Focalpoint Partners).

Source

Christian Angermayer's private multi-strategy investment firm with over $3.5B under management across life sciences, fintech and future tech. Angermayer founded atai Life Sciences, and Apeiron is one of its largest shareholders — among the most influential capital backers in psychedelics.

Source

Venture firm founded in 2019 that ran one of the first dedicated psychedelic business incubators and invests across mental-health treatment and healthcare infrastructure.

Source

Satori Neuro is the mental-health and neuroscience thematic strategy of Dallas-based conscious-capitalism firm Satori Capital, led by CIO Dr. Amy Kruse. It targets psychedelic medicine, brainwave devices and VR/AR therapeutic protocols, raising about $10.3M for the fund.

Source

Peter Thiel's private investment vehicle was an early and influential backer of psychedelic drug development, anchoring atai Life Sciences' $125M round and investing in COMPASS Pathways.

Source

Venture investor active in the psychedelic sector, noted as a backer of Beckley Psytech alongside other psychedelic-focused funds.

Source

Global pharmaceutical company that made big pharma's first substantive entry into psychedelics, agreeing in August 2025 to acquire Gilgamesh Pharmaceuticals' next-generation psychedelic candidate bretisilocin (GM-2505) for major depressive disorder in a deal worth up to $1.2B.

Source

Global pharmaceutical company that entered psychedelics in July 2026 by agreeing to acquire AtaiBeckley (formed from the 2025 merger of atai Life Sciences and Beckley Psytech) for roughly $2.8B upfront, up to $3.8B with milestones, gaining the 5-MeO-DMT depression candidate BPL-003.

Source

Japanese pharmaceutical company active in neuropsychiatry that has moved into psychedelics, acquiring Canadian psychedelic biotech Mindset Pharma and, in 2026, methylone developer Transcend Therapeutics to strengthen its next-generation psychiatric pipeline.

Source